SIGNY, Switzerland & MARSEILLES, France--(BUSINESS WIRE)--Feb. 6, 2004--Haemonetics Corporation and Hemosystem SA announced an agreement making Haemonetics the exclusive sales and marketing partner for Hemosystem's Scansystem(TM) technology in Europe, the Middle East, Africa and Latin America. The agreement is effective for just over 3 years. The companies did not disclose other terms of the agreement.
The Scansystem technology screens blood components for bacteria. Bacterial contamination is the second most common cause of transfusion-related death and so this screening, known as bacterial detection, is becoming the standard of practice around the world. The Scansystem has CE Mark clearance for use in Europe on bacterial screening of platelets.
"Haemonetics will leverage its market strength in Europe and other parts of the world to deliver the Scansystem technology to blood collectors as they implement new programs to provide the safest blood possible to their patients," said Dr. Ulrich Eckert, President of Haemonetics Europe.
"What distinguishes the Scansystem technology from other bacterial screening tests is its ability to provide a bacterial result for platelet products in less than 90 minutes (with testing occurring anytime from 30 hours post-donation on). This enables blood collectors to release the tested product for transfusion within the shortest possible time," he continued. This allows hospitals to have platelet products more readily available for transfusion.
There are approximately 1.7 million doses of platelets transfused in Europe annually. African and Latin American markets are smaller. One Scansystem screen can test 3 units of platelets simultaneously.
Several national European blood collection organizations and public health authorities are interested in implementing bacterial screening methods. Local European evaluations with Scansystem are scheduled for early 2004.
Hemosystem expects to submit an application for the Scansystem for use in bacterial detection of platelets to the U.S. Food and Drug Administration in 2004. Additionally, the Company is developing the technology for use in the bacterial detection of red cells.
For more information, visit the Haemonetics website:
Frequently Asked Questions http://www.haemonetics.com/site/pdf/hemosystem_faqs.pdf Bacterial Detection Fact Sheet: http://www.haemonetics.com/site/pdf/bd_fact_sheet.pdf Haemonetics (NYSE: HAE - News) is a global company engaged in the design, manufacture and worldwide marketing of automated blood processing systems. These systems address important medical markets: surgical blood salvage, blood component collection, plasma collection, and blood component safety.
Hemosystem S.A., a company founded in 1999 in Marseilles (France), focuses on the development of immediate detection of bacteria in blood and blood products. The Scansystem combines a proprietary disposable kit for processing the sample and fluorescently labeling the bacteria and an analyzer which scans the membrane; bacteria in platelet products are detected at 30 hours after collection. Future applications for Scansystem like bacterial detection within Red Cell units are currently under development. For further information, consult Hemosystem's website at http://www.hemosystem.com.
This release contains forward looking statements that involve risks and uncertainties, including technological advances in the medical field and standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand, market acceptance, regulatory uncertainties, the effect of economic and political conditions, the impact of competitive products and pricing, blood product reimbursement policies and practices, foreign currency exchange rates, changes in customers' ordering patterns, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate and other risks detailed in the Company's filings with the Securities and Exchange Commission. The forward-looking statements are based on estimates and assumptions made by management of the Company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results and experience could differ materially from the forward-looking statements.
Haemonetics Corporation U.S. Contact: Julie Fallon, 781-356-9517 Alt. Tel. 617-320-2401 email@example.com or European Contact: Dr. Ulrich Eckert, +49 (89) 78580710
Source: Haemonetics Corporation